Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Chataway

Showing results (61-70 of 182) with videos related to

Pageof 19
Sort By:
Archives of Neurology|February 14, 2007
Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entityGeorge K Tofaris, Tamas Revesz, Thomas S Jacques, et al.
Neurology|February 23, 2018
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosisJeremy Chataway, Keith Martin, Kevin Barrell, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 22, 2014
Lymphomatosis cerebri: a treatable cause of rapidly progressive dementiaAmit Samani, Indran Davagnanam, Oliver Charles Cockerell, et al.
The Lancet. Neurology|November 20, 2021
Trials for neurodegenerative diseases: time to innovateArpan R Mehta, Jeremy Chataway, Suvankar Pal, et al.
The Lancet. Neurology|June 20, 2006
Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trialJeremy Chataway, Bernadette Porter, Afsane Riazi, et al.
The Lancet. Neurology|February 16, 2024
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challengesJeremy Chataway, Thomas Williams, Vivien Li, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 4, 2020
Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-yearsAnnie Hawton, Elizabeth Goodwin, Kate Boddy, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2026
Recalibration and external validation of vascular risk calculators for multiple sclerosis: A population-based study using CPRD data in England, 1987-2023Raffaele Palladino, Ruth Ann Marrie, Giuseppina Affinito, et al.
Neuroreport|May 19, 2006
Space re-exploration in hemispatial neglectAndrew Parton, Paresh Malhotra, Parashkev Nachev, et al.
Clinical Rehabilitation|January 28, 2010
Psychological distress after stroke and aphasia: the first six monthsKaterina Hilari, Sarah Northcott, Penny Roy, et al.
Pageof 19

Showing results (61-70 of 182) with videos related to

Sort By:
Pageof 19
Archives of Neurology|February 14, 2007
Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entityGeorge K Tofaris, Tamas Revesz, Thomas S Jacques, et al.
Neurology|February 23, 2018
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosisJeremy Chataway, Keith Martin, Kevin Barrell, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 22, 2014
Lymphomatosis cerebri: a treatable cause of rapidly progressive dementiaAmit Samani, Indran Davagnanam, Oliver Charles Cockerell, et al.
The Lancet. Neurology|November 20, 2021
Trials for neurodegenerative diseases: time to innovateArpan R Mehta, Jeremy Chataway, Suvankar Pal, et al.
The Lancet. Neurology|June 20, 2006
Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trialJeremy Chataway, Bernadette Porter, Afsane Riazi, et al.
The Lancet. Neurology|February 16, 2024
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challengesJeremy Chataway, Thomas Williams, Vivien Li, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 4, 2020
Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-yearsAnnie Hawton, Elizabeth Goodwin, Kate Boddy, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2026
Recalibration and external validation of vascular risk calculators for multiple sclerosis: A population-based study using CPRD data in England, 1987-2023Raffaele Palladino, Ruth Ann Marrie, Giuseppina Affinito, et al.
Neuroreport|May 19, 2006
Space re-exploration in hemispatial neglectAndrew Parton, Paresh Malhotra, Parashkev Nachev, et al.
Clinical Rehabilitation|January 28, 2010
Psychological distress after stroke and aphasia: the first six monthsKaterina Hilari, Sarah Northcott, Penny Roy, et al.
Pageof 19